Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. (Nasdaq: CLDX) is a biopharmaceutical company developing therapeutic antibodies for severe inflammatory, allergic, autoimmune and other diseases, with a focus on conditions driven by mast cells. Its lead candidate, barzolvolimab, is a monoclonal antibody that targets the KIT receptor and is… From the company’s description.
Over the twelve months to Sep 30, 2026, Celldex Therapeutics, Inc. reported revenue of $0.16M, down 93.9% from a year earlier, and a net loss of $309.06M. Operations used $251.97M in cash. In fiscal 2025, it reported revenue of $1.54M, down 78.0% from fiscal 2024, and a net loss of $258.76M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Celldex Therapeutics, Inc. does
In the company’s own words
Celldex Therapeutics, Inc. (Nasdaq: CLDX) is a biopharmaceutical company developing therapeutic antibodies for severe inflammatory, allergic, autoimmune and other diseases, with a focus on conditions driven by mast cells. Its lead candidate, barzolvolimab, is a monoclonal antibody that targets the KIT receptor and is being studied in chronic spontaneous and inducible urticaria, prurigo nodularis and atopic dermatitis. Celldex is also developing CDX-622, a bispecific antibody that targets TSLP and SCF, and uses its bispecific antibody platform to pursue additional candidates for inflammatory diseases. The company’s research and development programs serve patients with significant unmet treatment needs; it has no commercial product sales. Celldex reports its business as one operating segment. For the fiscal year ended December 31, 2025, it reported $[missing] million in revenue. Its website is https://www.celldex.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- HAMPTON, NJ
- Fiscal year end
- December
- CIK
- 744218
- SIC
- 2835
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Celldex Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Celldex Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Celldex Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Celldex Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Celldex Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”